Moderna has submitted a conditional marketing approval (CMA) request to the European Medicines Agency for the use of its Covid-19 vaccine among adolescents. The submission comes after a Phase II/III study of the mRNA-1273 vaccine in adolescents aged between 12 and 18 years in the US. In May, the company announced that its Phase II/III TeenCOVE study of Moderna’s vaccine in adolescents met its primary immunogenicity endpoint.
The Ministry of Health of the Republic of Congo has approved the Russian-produced single-dose Sputnik Light vaccine to fight Covid-19. Sputnik Light is the first component of the Sputnik V vaccine and has shown 79.4% efficacy according to analysed data from 28 days after the administration of a single jab. The data was drawn from Russians vaccinated with a single jab and having not yet received the second, the Russian Direct Investment Fund said.
Go deeper with GlobalData
